OncoMed Pharmaceuticals Inc. (OMED) Earns “Market Perform” Rating from Leerink Swann
Other equities analysts have also issued reports about the stock. Jefferies Group raised their price target on shares of OncoMed Pharmaceuticals from $15.00 to $16.00 and gave the stock a buy rating in a research report on Wednesday, August 10th. Cantor Fitzgerald reaffirmed a buy rating and set a $16.00 price target on shares of OncoMed Pharmaceuticals in a research report on Thursday, July 14th. HC Wainwright started coverage on shares of OncoMed Pharmaceuticals in a research report on Thursday, September 22nd. They set a buy rating and a $20.00 price target on the stock. Finally, Zacks Investment Research lowered shares of OncoMed Pharmaceuticals from a buy rating to a hold rating in a research report on Saturday. Three investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. OncoMed Pharmaceuticals presently has a consensus rating of Buy and a consensus target price of $19.25.
OncoMed Pharmaceuticals (NASDAQ:OMED) opened at 9.74 on Friday. The firm’s market capitalization is $361.28 million. OncoMed Pharmaceuticals has a 12 month low of $8.07 and a 12 month high of $23.98. The stock’s 50 day moving average is $10.17 and its 200-day moving average is $11.51.
OncoMed Pharmaceuticals (NASDAQ:OMED) last released its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported ($0.77) EPS for the quarter, hitting analysts’ consensus estimates of ($0.77). OncoMed Pharmaceuticals had a negative net margin of 409.54% and a negative return on equity of 1,307.23%. The business had revenue of $5.92 million for the quarter, compared to analyst estimates of $9.48 million. During the same period last year, the firm earned ($0.81) earnings per share. OncoMed Pharmaceuticals’s revenue for the quarter was up 26.3% compared to the same quarter last year. Equities analysts anticipate that OncoMed Pharmaceuticals will post ($3.23) earnings per share for the current fiscal year.
A number of large investors have recently bought and sold shares of the company. Alps Advisors Inc. increased its stake in OncoMed Pharmaceuticals by 25.7% in the second quarter. Alps Advisors Inc. now owns 42,562 shares of the biopharmaceutical company’s stock valued at $524,000 after buying an additional 8,701 shares in the last quarter. Schwab Charles Investment Management Inc. increased its stake in OncoMed Pharmaceuticals by 1.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 42,821 shares of the biopharmaceutical company’s stock valued at $528,000 after buying an additional 588 shares in the last quarter. Candriam Luxembourg S.C.A. increased its stake in OncoMed Pharmaceuticals by 59.0% in the second quarter. Candriam Luxembourg S.C.A. now owns 167,000 shares of the biopharmaceutical company’s stock valued at $2,056,000 after buying an additional 62,000 shares in the last quarter. BVF Inc. IL increased its stake in OncoMed Pharmaceuticals by 35.1% in the first quarter. BVF Inc. IL now owns 1,339,336 shares of the biopharmaceutical company’s stock valued at $13,541,000 after buying an additional 347,903 shares in the last quarter. Finally, A.R.T. Advisors LLC acquired a new stake in OncoMed Pharmaceuticals during the first quarter valued at approximately $832,000. Institutional investors and hedge funds own 31.94% of the company’s stock.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals, Inc (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc.
Receive News & Stock Ratings for OncoMed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoMed Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.